Cargando…

TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications

SIMPLE SUMMARY: Toll-like receptor 4 (TLR4) and phosphorylated signal transducer and activator of transcription protein 3 (pSTAT3) play a prominent role in cancer inflammation and anti-tumor immune response, and their therapeutic targeting is considered a promising strategy for the management of bre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadaki, Maria A., Monastirioti, Alexia, Apostolopoulou, Christina A., Aggouraki, Despoina, Papadaki, Chara, Michaelidou, Kleita, Vassilakopoulou, Maria, Alexakou, Katerina, Mavroudis, Dimitrios, Agelaki, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869985/ https://www.ncbi.nlm.nih.gov/pubmed/35205801 http://dx.doi.org/10.3390/cancers14041053

Ejemplares similares

Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab
por: Monastirioti, Alexia, et al.
Publicado: (2022)

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2020)

A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer
por: Monastirioti, Alexia, et al.
Publicado: (2021)

Investigating the Role of CTCs with Stem/EMT-like Features in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
por: Papadaki, Maria A., et al.
Publicado: (2022)

Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer
por: Michaelidou, Kleita, et al.
Publicado: (2020)

MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer
por: Thomopoulou, Konstantina, et al.
Publicado: (2021)

MicroRNAs Regulating Tumor and Immune Cell Interactions in the Prediction of Relapse in Early Stage Breast Cancer
por: Papadaki, Chara, et al.
Publicado: (2021)

Circulating MicroRNAs Regulating DNA Damage Response and Responsiveness to Cisplatin in the Prognosis of Patients with Non-Small Cell Lung Cancer Treated with First-Line Platinum Chemotherapy
por: Papadaki, Chara, et al.
Publicado: (2020)

Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer
por: Papadaki, Chara, et al.
Publicado: (2019)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
por: Papadaki, Maria A, et al.
Publicado: (2020)

Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study
por: Rounis, Konstantinos, et al.
Publicado: (2023)

Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome
por: Polioudaki, Hara, et al.
Publicado: (2020)

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Expression of tSTAT3, pSTAT3(727), and pSTAT3 (705) in the epithelial cells of hormone‐naïve prostate cancer
por: Krzyzanowska, Agnieszka, et al.
Publicado: (2019)

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2018)

Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer
por: Papadaki, Chara, et al.
Publicado: (2022)

Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2022)

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
por: Kallergi, G., et al.
Publicado: (2018)

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2011)

IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy
por: Chai, Dafei, et al.
Publicado: (2022)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

Direct targets of pSTAT5 signalling in erythropoiesis
por: Gillinder, Kevin R., et al.
Publicado: (2017)

Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer
por: Yang, Chunmei, et al.
Publicado: (2013)

Potential Refinement of Recurrence Score by pSTAT3 Status
por: Grinshpun, Albert, et al.
Publicado: (2022)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer
por: Papadaki, Maria A, et al.
Publicado: (2014)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Hypoxia-inducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2009)

The assessment of correlation and prognosis among (18)F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients
por: Kaida, Hayato, et al.
Publicado: (2018)

pSTAT1 Is Activated during the Progression of IgA Nephropathy
por: Tao, Jianling, et al.
Publicado: (2022)

Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma
por: Andreev, Katerina, et al.
Publicado: (2016)

Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma
por: Andreev, Katerina, et al.
Publicado: (2015)

May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
por: Psilopatis, Iason, et al.
Publicado: (2022)

Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitis
por: Pérez-Baos, Sandra, et al.
Publicado: (2019)

Dynamic Changes in pStat3 Are Involved in Meiotic Spindle Assembly in Mouse Oocytes
por: Haraguchi, Seiki, et al.
Publicado: (2020)

IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation
por: Lambert, Katharina, et al.
Publicado: (2022)

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
por: Karachaliou, Niki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_46vv7p8prhabop5cn9pe5kh0pt